Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
TheBody.com/The Body PRO Covers CROI 2009, February 8-11, 2009
  
  • Email Email
  • Comments Comments
  •  (1)
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Topical PrEP Comparison: Tenofovir Alone May Be as Effective as Tenofovir/FTC, Study Finds

An Interview With Walid Heneine, Ph.D.

February 9, 2009

Multimedia Toolbox

Listen to Audio (5 min.)

Please note: These files can be quite large. Allow some time for them to download.

My name is Dr. Walid Heneine. I work at the U.S. Centers for Disease Control and Prevention [CDC] in the Division of HIV/AIDS Prevention. Thank you very much for having me today to speak about our work related to topical prophylaxis with gels containing antiretroviral drugs.

Pre-exposure prophylaxis, or PrEP, is one of the most promising areas of HIV prevention and research. [There] are several trials that are now evaluating PrEP either taken orally or topically through gels. These trials are currently underway around the world; they will give us some first answers on the efficacy and safety of PrEP, [including] how well they can prevent HIV transmission.

Walid Heneine, Ph.D.
Walid Heneine, Ph.D.
However, animal studies like the one that we are discussing today are a critical part of the preparations for the next generation of PrEP research. Our study compares the effectiveness of a topical gel containing one drug, tenofovir [TDF, Viread], with another gel containing a combination of two drugs, tenofovir and FTC [emtricitabine, Emtriva].1 We looked at the effectiveness of these two gels in a monkey model against vaginal transmission of the simian form of HIV.

Advertisement
When applied 30 minutes before challenge with [i.e., exposure to] the virus, we found that both gels completely protected against vaginal transmission, suggesting that you can achieve a very high level of protection with gels containing single drugs.

Obviously, this was somewhat of a surprising result. Previous animal studies that we have done with oral PrEP all suggested that drug combinations are more effective than single drugs, so this is the first instance in which we're seeing that you can achieve a high level of protection by topically applying gel that contains a single drug.

This is very promising. We are awaiting right now the human data from these gel studies, so that we can see how well the human data correlates with the monkey data. All this work we are doing right now will help us prepare for the next PrEP trial research.

How do you explain the difference compared to previous studies, in which they seemed to show that it was absolutely better to use a combination drug?

We think it has to do with the amount of drug that the gel delivers to the point of entry for the virus -- vaginal tissues, in this case. We think that the concentration of the tenofovir in the gel is much higher than when you take tenofovir orally, so you have higher levels of drug where the virus enters from applying the gel topically versus when you are taking a pill orally. That's the possible explanation. We are now generating drug-level data [in which we] follow oral dosing of the pill compared to topical application with the gel to further explain those findings.

What's the consistency of this gel?

This is like a normal gel that you could use like for lubrication: It's viscous, clear, odorless. It has a good consistency.

It's similar to other microbicides being developed?

It's similar to other microbicides. However, the active ingredient in them is now antiretroviral drugs. This is the new generation of microbicide gels that use new classes of active components, namely these antiretroviral drugs.

Did you see any adverse effects?

No. We did acute toxicity studies, drug-level studies and so forth. At least in the monkeys, we have not seen any adverse effect. Clearly, all these products, particularly 1% tenofovir, are now in safety studies in humans -- for vaginal application as well as for rectal application.

Thank you very much.

Thank you for having me.

This transcript has been edited lightly for clarity.


Reference

  1. Heneine W, Dobard C, Parikh U, et al. Complete Protection against Repeated Vaginal Simian HIV Exposures in Macaques by a Topical Gel Containing Tenofovir Alone or with Emtricitabine. In: Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2009; Montréal, Canada. Abstract 46.

  
  • Email Email
  • Comments Comments
  •  (1)
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by TheBodyPRO.com. It is a part of the publication The 16th Conference on Retroviruses and Opportunistic Infections.
 
See Also
More News and Research on HIV Medications for HIV Prevention

Reader Comments:

Comment by: Simon Watney (London UK) Wed., Aug. 12, 2009 at 7:56 pm EDT
May I question the fundamental assumption of this, and all similar pro-Prep propaganda, namely the idea that the future of HIV education somehow lies in antretroviral drug prophylaxis? Nothing could be more dangerous than such advice, which both undermines the need for condom use (especially amongst high risk groups), and plays straight into the self-interested hands of a corrupt research establishment which has never shown any serious interest in HIV education. 25 years ago strikingly similar voices preached similar messages about the supposedly miraculous benefits of antimicrobioal interventions, as some of us well recall. Is there nobody else left out there with any long-term memory of this epidemic? If safer sex education isn't working it's the fault of bad education and bad educators, who ignore the need for more and better HIV education rooted in the real world of sexual pleasure and behaviour. The whole Prep-aganda industry amounts to nothing more than a form of dangerously distracting magical thinking which seeks to substitute drugs for demonstrably effective prevention work.
Reply to this comment


Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement